The present invention provides anti-N3pGlu Aß antibodies or antigen-binding fragment thereof. In addition  the present invention provides the use of the anti-N3pGlu Aß antibodies or antigen-binding fragment thereof for the treatment of Alzheimers disease.

Provided are novel methods and formulations for enhancing feed efficiency and reducing mortality in food animals.

The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use. ...

The present disclosure relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1 ), useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics. Said antibodies have specific variable chain sequences. According to the experimental re...

The present invention relates to a c-Met inhibitor (disclosed herein) or a pharmaceutically acceptable salt thereof useful in treating cancer mediated by activity of c-Met receptors.

The present invention provides glucagon and GLP 1 co agonist compounds that are useful in the treatment of type 2 diabetes obesity nonalcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH). P 20637

The present invention provides 3-indazoyl-4-pyridylisothiazoles or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and methods of using the same, as well as processes for preparing the same, and intermediates thereof.

The present invention provides compounds of the formula below: where A X and R1 R6 are as described herein a pharmaceutical salt thereof and a pharmaceutical composition containing this compound; methods of treating pain associated with osteoarthritis using one of the compounds or a pharmaceutically acceptable salt ...

The present invention relates to compounds with an extended duration of action at the glucagon receptor as compared to native glucagon. Specifically provided are glucagon receptor agonists with modifications to the structure of native glucagon introduced to selectively agonize the glucagon receptor over an extended ...

The present invention provides a compound of the formula below or a pharmaceutical salt thereof methods of treating diabetes using the compound and a process for preparing the compound.

Monoclonal antibodies to human tau aggregate compositions comprising such tau antibodies and methods of using such tau antibodies for the treatment of neurodegenerative diseases including Alzheimer s disease Progressive Supranuclear Palsy and Pick s disease.

The present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carriér, diluent, or excipient; and methods for treating physiological disorders, particula...

The compound, ((3-2-amino-1,2-dioxoethyl)-2-ethyl-l-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid morpholino-N-ethyl ester, is disclosed together with its use as a highly bioavailable indole compound for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock. ...

The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and pro...

The invention provides the use of a compound of the(Figure Remove) R: is hydrogen, Q-C4 alkyl, bromo, fluoro, chloro or iodo; or a pharmaceutically-acceptable salt thereof for the manufacture of a medicament for immunosuppressive therapy of the human or animal body.

The present invention relates to certain benzimidazole compounds of Formula I, or pharmaceutically acceptable salts thereof, that inhibit Janus kinase 1 (JAKI), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat certain types of cancer.

This invention provides a process to prepare 10,11-(optionally substituted)methanodibenzosuberane derivatives. The invention also provides an intermediate in this process.

The invention provides crystalline (2S) 3 [(3S 4S) 3 [(1R) 1 hydroxyethyl] 4 (4 methoxy 3 {[1 (5 methylpyridin 2 yl)azetidin 3 yl]oxy}phenyl) 3 methylpyrrolidin 1 yl] 3 oxopropane 1 2 diol and pharmaceutical compositions thereof. The invention further provides methods of using this compound to treat overactive bladd...

The present invention provides a compound of Formula I or hydrate thereof useful for the treatment of diabetes.

A dual H1/5 HT 2A receptor antagonist of the formula: its uses and methods for its preparation are described.

A pharmaceutical delivery apparatus with an automatic syringe retraction following a manually controlled injection. The apparatus includes a housing, a syringe carriage, a medication-filled syringe held within the carriage, the syringe needle tip being 5 disposed within the housing when the carriage is in a first ...

The present invention includes a method for decreasing hot flashes in a human female by administering fluoxetine to that female. Another aspect of the invention is a method for decreasing hot flashes in a human female undergoing raloxifene administration by administrating fluoxetine to that female. Another aspect ...

The present disclosure provides animal feed supplements comprising a therapeutically effective amount of monensin and a solvent wherein the supplement is a solution. The disclosure also provides food compositions comprising a therapeutically effective amount of monensin a solvent and an animal feed methods of admini...

The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described. ...

The present invention provides processes and intermediates for the preparation of {1 (ethylsulfonyl) 3 [4 (7H pyrrolo[2 3 d]pyrimidin 4 yl) 1H pyrazol 1 yl]azetidin 3 yl}acetonitrile: (I)

Pharmaceutical compositions and methods are provided for the treatment and prevention of bone loss diseases including osteoporosis in a mammal.

The present invention provides a compound or a pharmaceutically acceptable salt or hydrate and a pharmaceutical composition containing said compound or a pharmaceutically acceptable salt or hydrate useful as a Notch pathway signaling inhibitor for the treatment of cancer

ABSTRACT This invention provides a single dose oral formulation of spinosad for the extended control of a C. infestation on a cat at a predictable dose of spinosad that is suitable for administration once every 30 days (. one month). The invention also provides methods of using the formulation of spinosad. ...

The invention provides certain azetidinyloxyphenylpyrrolidine compounds particularly compounds of formula I and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat overactive bladder.

The present invention provides certain imidazole carboxamide derivatives, pharmaceutical compositions thereof, methods of using the same for preparing a medicament useful in the treatment of conditions associated with the mGlur2 receptor, such as depression and anxiety, and processes of the following Formula (I) for...

The present invention provides novel trimethylammonium compounds of the Formula: (I) methods of making these compounds methods of using the compounds for preparation of tau imaging agents and preparation of tau imaging agent formulations.

The present invention provides a method of treating a cognitive or neurodegenerative disease comprising administering to a patient in need of such treatment an effective amount of a compound of the formula I or a pharmaceutically acceptable salt thereof; in combination with an effective amount of an anti N3pGlu Abet...

A dual H1 inverse agonist/5 HT receptor antagonist of the formula (I) its uses and methods for its preparation are described.

The present invention provides compounds of Formula I or a pharmaceutical salt thereof; methods of treating osteoarthritis and the pain associated with osteoarthritis using the compounds; and processes for preparing the compounds.

The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.

The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.

The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.

The present invention provides novel ROR gamma t inhibitors and pharmaceutical compositions thereof:

Pyrido[2 3 d]pyrimidin 4 one compounds formulations containing those compounds and their use as tankyrase 1 and 2 inhibitors Formula (I).

The present invention provides a novel compound of the formula: methods of making this compound, methods of using this compound for tau imaging, and preparations of tau imaging formulations.

The present invention is directed to a compound of the formula or a pharmaceutically acceptable salt thereof; and also to compounds of formula I: or a pharmaceutically acceptable salt thereof.

The present invention provides 1 2 benzothiazole compounds particularly useful in the treatment of diabetic nephropathy and other chronic kidney disorders and other diabetic complications.

The present invention provides compounds of Formula 1 or a pharmaceutically acceptable salts thereof where R X A E and G are as described herein methods of preparing the compounds and use of the compounds to treat pain and/or inflammation.

The present invention provides thieno[2 3 c]pyrrol 4 one compounds that inhibit activity of extracellular signal regulated kinase (ERK) and may be useful in the treatment of cancer.

The present invention provides crystalline (R)  (E) 2 (4 (2 (5 (1 (3 5 dichloropyridin 4 yl) ethoxy)  1H indazol 3 yl) vinyl)  IH pyrazol  1 yl) ethanol useful in the treatment of cancer.

A locking assembly for a medication dispensing device including a housing a drive member a medication cartridge having a barrel holding medication between a movable plunger and a septum and a dose delivery mechanism for controlling the advancement of the drive member. The locking assembly in one form includes a lock...

The present invention relates to a synthetic intermediate of the formula: and its use in a synthetic process to make compounds of the formula .

The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I  uses of compounds of Formula I and method of using compounds of Formula I.

The present invention provides a novel compound useful in the treatment of hypoglycemia.

The present invention provides compounds of the formula wherein R is selected from the group consisting of H and CH; R is selected from the group consisting of H and CH; R is selected from the group consisting of H C C alkyl O(CH)SOCH O(CH)OCH O(CH)C(CH)OH CN and OCF; or a pharmaceutical salt thereof methods of trea...

3332The present invention provides a compound of the Formula: wherein X is selected from the group consisting of R is selected from the group consisting of H and CH; R1 is selected from the group consisting of H CH F Cl OCH C(O)OH C(O)NH or a pharmaceutically acceptable salt thereof.

The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof. Also the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable diluent or carrier. The prese...

The present invention provides compounds of Formula (I) below: and analogues thereof where the various substituent groups R1 R2 R3 R4 R5 A and X are described herein; or a pharmaceutical salt thereof; a method of treating a condition such as hypertriglyceridemia and a process for preparing the compounds. ...

The present invention provides novel mGlu2/3 agonists of formula (I) useful in the treatment of neurological or psychiatric disorders.

The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 (GLP 1) and may be useful for treating type 2 diabetes mellitus (T2D).

The present invention provides compounds of Formula I or a pharmaceutical salt thereof methods of treating hypertriglyceridemia using the compounds; and a process for preparing the compounds.

Monoclonal antibodies are provided that selectively bind human hepcidin-25 and are characterized as having high affinity for human hepcidin-25 and strong human mature hepcidin neutralizing properties. The antibodies of the invention are useful therapeutically for increasing serum iron levels, reticulocyte count, red...

The present invention provides a combination therapy comprising the compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for use in the treatment of glioblastoma multiforme, a...

The present invention provides a tosylate salt of N [3 [(4aR 7aS) 2 amino 6 (5 fluoropyrimidin 2 yl) 4 4a 5 7 tetrahydropyrrolo[3 4 d][1 3]thiazin 7a yl] 4 fluoro phenyl] 5 methoxy pyrazine 2 carboxamide.

The present invention provides a combination therapy comprising the compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for use in the treatment of glioblastoma multiforme, a...

The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine: where A is C(H)= or -N= and R1-7 are as defined herein.

The invention provides certain 3 substituted 6 (pyridinylmethoxy) pyrrolopyridine compounds particularly compounds of formula I and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat Parkinsons disease Formula (I).

The present invention provides novel tetrasubstituted pyridazine hedgehog pathway antagonists useful in the treatment of cancer.

As ORL-1 receptor antagonist of the formula I, its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful; in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have als...

The present invention provides the compound l (3 3 Dimethylbutyl) 3 (2 fluoro 4 methyl 5 (7 methyl 2 (methylamino)pyrido[2 3 d]pyrimidin 6 yl)phenyl)urea or a pharmaceutically acceptable salt thereof that inhibits Raf and therefore may be useful in treating cancer.

The present invention provides novel tetrasubstituted pyridine hedgehog pathway antagonists of the following formula I (I) or a pharmaceutically acceptable salt thereof, wherein: X is C-R1 or N; R1 is hydrogen, fluoro or cyano; R2 is formula II (II), piperidinyl, or gem di-F-substituted cyclohexyl; R3 is methyl or t...

Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of human FPN1, and which are effective in maintaining or increasing the transport of iron out of mammalian cells and/or maintaining or increasing the level of serum iron, reticulocyte count, red blood cell...

The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers. E.e. glioblastoma, breast cancer, multiple myeloma, prostate, cancer, and leukemias.

Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNFa) and Interleukin 17 (IL 17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Rheumatoid Arthritis (RA) Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS). ...

A crystalline 2-(6-Methyl-pyridin-2-yl)-3-[6-amido-quinolin-4-yl)-5 6-dihydro- 4Hpyrrolo [ 1  2-b] pyrazole monohydrate of formula 1

The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, depression, and generalized anxiety disorder. The novel agonists are represented by the formula.

The present invention provides oxazolo[5 4 b]pyridin 5 yl compounds useful in the treatment of cancer.

This invention relates to pyrazole compounds or pharmaceutically acceptable salts thereof. Compounds of this invention are inhibitors of methionine aminopeptidase 2 (MetAP2) and dipeptidyl peptidase 4 (DPP 4). MetAP2 is a metalloproteinase that cleaves initiator methionine from nascent peptide emerging from the ribo...

This invention provides compounds of formula (I) : or a pharmaceutically acceptable salt thereof as inhibitors of diacylglycerol acyltransferase 1 (DGAT-1); as well as a method for treating obesity, a method for treating diabetes, and a pharmaceutical composition.

A compound of the formula: ; and pharmaceutical compositions for the treatment of diabetes.

A dispensing device for dispensing medication from a medication container. The dispensing device includes a housing, a drive member engageable with the medication container, at least one first ramp surface fixed relative to the housing, a driver movable within the housing to move the drive member for forcing med...

The invention provides certain azetidinyloxyphenylpyrrolidine compounds particularly compounds of formula I wherein R is hydrogen or methyl and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I to treat overactive bladder.

ABSTRACT The present invention provides an Oxyntomodulin peptide analogue useful in the treatment of diabetes and/or obesity.

A delay mechanism for an automatic injection device having a housing and a medication filled syringe. The delay mechanism includes a shuttle a follower a damping compound at least one biasing member and a biased plunger element. When moved in the device housing from a first location to a second location the biased p...

Crystalline   R-2-(4-cyclopropanesulfonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide and methods of its preparation and use are disclosed.

The present invention provides a compound of Formula (II): wherein X represents the following: or a pharmaceutically acceptable salt thereof.

The present invention provides a compound of Formula (I): Formula (I) and methods for treating physiological disorders, particularly congestive heart failure, hypertension, diabetic nephropathy, or chronic kidney disease. The present inv ention relates to nonsteroidal mineralocpiticoid receptor antagonists. ...

The present invention provides an aminopyrazole compound, or a pharmaceutically acceptable salt thereof or a solvate of the salt, that inhibits Chk1 and is useful in the treatment of cancer.

The present invention relates to HDAC2 as a biological marker for treating cancer in a patient using Enzastaurin as a single agent or in combination with a Class I selective HDAC inhibitor.

A dual H1/5 HT receptor antagonist of the formula: its uses and methods for its preparation are described.

This present invention relates to pharmacologically potent and stable human fibroblast growth factor 21 (FGF21) proteins pharmaceutical compositions comprising FGF21 proteins and methods for treating type 2 diabetes obesity dyslipidemia and/or metabolic syndrome using such proteins.

The invention provides methanol,ethanol, and 1-propanol solvates of olanzapine and a process for using such solvates.

The present invention provides Oxyntomodulin peptide analogues useful in the treatment of diabetes and/or obesity.

The present invention provides a compound of the Formula II: wherein A is: * R is CH3 CF or F; * R is H CH3 or F; * R is CH3 OCH  OH F; R is OH or CH H; and * X is CH or N; These compounds are selective EP4 inhibitors and are useful for the treatment of inflammatory conditions such as arthritis. ...

The invention is a composition of human insulin or insulin analog that includes treprostinil and that has faster pharmacokinetic action than commercial formulations of existing insulin analog products.

The present invention relates to novel variants of human glial cell-derived neurotrophic factor (GDNF) and methods for their use.

An injection device for injecting a medicament includes a housing a dose setting member (20) movable to set a dose to be injected and a signal part (7). The signal part rotates from a first rotational position to a second rotational position to increase loading on a spring or spring arm when a dose is set due to rot...

1234The present invention provides a compound of Formula (III): wherein A is: Formula (A) (B) (C) (D) (E) or (F); and Z R R R and R are as defined herein or a pharmaceutically acceptable salt thereof.

The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor        (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analog...

A serotonin and norepinephrine reuptake inhibitor of the formula: , its uses, and methods for its preparation are described.

The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating or preventing physiological disorders, partic...

The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.

The present invention provides vinyl indazoiyl compounds useful in the treatment of cancer.

Provided are dihydroisoxazole compounds I useful for controlling parasites both in animals and agriculture. Further provided are methods for controlling parasite infestations of an animal by administering an effective amount of a compound as described above or a pharmaceutically acceptable salt thereof to an animal ...

1A TARP ?8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N; A is; and R is as defined herein; its pharmaceutically acceptable salts uses and methods for its preparation are described.

The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder schizophrenia and generalized anxiety disorder.

An automatic injection apparatus including a delay mechanism for properly delivering medication prior to the needled syringe of the apparatus being retracted. In one form  the delay mechanism includes a shuttle ( 170 ) for the syringe  a follower ( 250 )  a locking member  a damping compound between the follower and...

The present invention provides BACE inhibitors of Formula (I): methods for their use, and intermediates and methods for their preparation.

The present invention provides aldosterone synthase inhibitors of the formula (I): intermediates methods for their preparation pharmaceutical preparations and methods for their use.

The present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart failure, ...

A compound of the formula (I) and pharmaceutical compositions for the treatment of pain.

The invention provides human engineered antibodies, antigen-binding fragments thereof, that bind to, and inhibit the activity of, human DKK-1, and which are effective in treating diseases in which pathogenesis is mediated by DKK-1.

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1Hbenzo[ d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety:............

The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition  the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of...

The present disclosure provides animal feed supplements comprising a therapeutically effective amount of monensin, a solvent, and a mineral mix, wherein the mineral mix is substantially free of monocalcium phosphate. In addition, the present dis - closure provides processes of preparing animal feed supplements and...

A cartridge for a medication dispensing device which includes multiple septums. The cartridge includes a body and an axially shiftable piston in fluid-tight engagement with an interior surface of the body. The first septum covers a dispensing port that opens to an interior hollow of the body at a proximal location. ...

The present invention relates to a crystalline variable hydrate of (S)-(-3-pyridinecarboxamide 6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy])-hemi-succinate, a pharmaceutical formulation containing said salt and to methods for treating obesity and/or Type 2 diabetes using said sal...

The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokineti...

Monoclonal anti-myostatin antibodies that preferentially bind myostatin over GDF-11, have strong binding affinity to myostatin and are resistant to chemical degradation. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment or prevention of various disor...

The present invention provides BACE inhibitors of Formula I: methods for their use  intermediates  and methods for their preparation.

The present invention provides novel compounds of Formula (I) and (I(a)), or the pharmaceutically acceptable salt thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes fo...

The present invention provides a novel compound of Formula I,or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compo...

Methods for using TRL V6 as a biomarker for the risk of weight gain associated with treatment of a patient with a pharmaceutical agent  as for example  olanzapine.

The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease.

Disclosed are glucagons-like peptide-1(GLP-1) compounds with modifications at one or more of the following positions: 7, 8, 12, 16, 18, 19, 20, 22, 25, 27, 30, 33, and 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed. (FIG). nil ...

Compounds and pharmaceutical compositions of Formula (I) by blockade of the CB1 receptors via an inverse agonism mechanism which are useful for reducing body weight in mammals, cognitive impairment associated with schizophrenia, mitigating treatment emergent weight gain observed during treatment with antipsychotics ...

The present invention relates to compounds of Formula I: pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.

The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and the use of such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome. ...

The present invention relates to compounds of the formula which are useful for treating conditions associated with mGluR3 receptors, pharmaceutical compositions thereof, and methods of using the same.

The stereospecific synthesis of a glycopeptide using a triply orthogonal protection scheme is described, in particular, the synthesis of N-acetylglucosaminyl- beta -[1,4]- N-acetylmuramylmonopeptide and derivatives thereof. The glycopeptide is useful for the preparation of GMDP and related compounds having a gluc...

The present invention relates to substituted benzopyran derivatives,stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor beta agonists. such agonists are useful for the treating estrogen recept...

The present invention provides a compound of the formula: Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising aa compound of Formula (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly reduced ...

A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments the...

The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compo...

The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising com...

A compound according to formula II and the pharmaceutically acceptable salts thereof and the method of treating cancer in a patient in need thereof by administration of said compound.

The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising com...

The present invention provides novel crystalline forms of {2-[l-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl-lH-[l,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone, compositions thereof, intermediates thereof, methods of using the same, processes for making the same, and processes for making intermediates...

The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. wherein: R1 hydrogen, hydroxy, halo, methyl, C1-C2 alkoxy, amino, or rnethylamino; R2 is hydrogen, halo, or cyano; R3 is hydrogen or halo;, R4 is hydrogen, ha...

The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity against a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also ...

The present invention provides kinase inhibitors of Formula (I). Wherein R1, R2, X and Z are as described herein, or a pharmaceutically acceptable salt thereof.

The present invention relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof which is useful for the treatment of conditions associated with glutamate hypofunction, such as psychiatric and neurological disorders.

The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein Ar1, L1 R1, q, X, R2, R3, R4, and R5 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with ob...

ABSTRACT TGF-BETA BINDING COMPOSITIONS The present invention provides very high affinity antibodies, or antigen-binding fragments thereof, that neutralize mature human TGF-&bgr;l, TGF-&bgr;2, and TGF-&bgr;3. The antibodies of the invention are useful for treating cell proliferative disorders in a mammal. ...

The present invention relates to novel, non-secosteroidal, phenyl-benzoxazole compounds of Formula (I) wherein the variables R, R', RP, RP3, LP1, LP2, ZP, RB, RB', LXB and ZXB are as hereinafter defined, their preparation, pharmaceutical compositions, and methods of use.

A compound of the formula (I); wherein the variables X1 to x10, R1 to R7 including R3, E, W, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases ...

The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other conditions.

The present invention is directed to compounds of the structural Formula: wherein: R1 is H or -C1-C3 alkyl; R2 is selected from the group consisting of -H, -C1-C4 alkyl, -C1-C3 alkyl-CF3, phenyl, and pyridinyl; and R3 is selected from the group consisting of -H, -C1-C4 alkyl, -C1-C3 alkyl-O-CH3, -CH2-cyclopropyl, -C...

A delay mechanism for staging the operation of an automatic injection apparatus to ensure medication contents are properly delivered prior to the needled syringe of the apparatus being retracted. In one form, the delay mechanism includes a shuttle, a follower, a locking member, a damping compound, and a driver and a...

Compounds of formula and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.

The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the produ...

This present invention provides a composition that is suitable for administration to a human subject comprising an anti-Aβ antibody that is free of Aβpeptide or that has acceptably low levels thereof, free of non-human Aβ peptide or that has acceptably low levels thereof, or having an undetectable concentration of A...

Humanized and chimeric antibodies are provided that specifically bind human sclerostin and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful for increasing bone mass, bone mineral density and bone strength and for the treatment of various disord...

The present invention provides dosing regimens for Propanoic Acid, 2-[4-[3-[2,5- dihydro-1-[(4-methylphenyl)methyl]-5-oxo-1H-1,2,4-triazol-3-yl]propyl]phenoxy]-2- methyl- and compositions thereof. A further embodiment of the present invention is a solid oral formulation of Propanoic Acid, 2-[4-[3-[2,5-dihydro-1-[...

The present invention provides novel crystalline forms of {2-[1-(3,5-bistrifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]- pyridin-3-yl}-(2-chlorophenyl)-methanone, compositions thereof, intermediates thereof, methods of using the same, processes for making the same, and processes for making in...

The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising com...

The present invention relates to a method of treating cancer in a patient comprising administering an effective amount of a Survivin antisense oligonucleotide in combination with an effective amount of an additional anti-cancer agent.

The present invention provides a pro-inflammatory synthetic polysaccharide antigen (SPA), or a pharmaceutically acceptable salt thereof, comprising a TLR2 -targeting synthetic peptidoglycan (PGN) moiety onto which a first epitope and a second epitope are each covalently attached. The first epitope comprises one or...

The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.

This invention relates to a series of tetracyclic derivatives, to processes for their preparation, pharmaceutical compositions containing them, and their use as therapeutic agents. In particular, the invention relates to tetracyclic derivatives which are potent and selective inhibitors of cyclic guanosine 3',5'- ...

The invention provides an amorphous, lyophilized, parenteral formulation of olanzapine (Fig.1)

The present invention relates to a crystalline variable hydrate of (S)-(-3-pyridinecarboxamide 6-[4-[2-[[3-(9H-carbazol-4-yloxy)-2-hydroxypropyl]amino]-2-methylpropyl]phenoxy])-hemi-succinate, a pharmaceutical formulation containing said salt and to methods for treating obesity and/or Type 2 diabetes using said salt...

The present invention provides Compound (I): Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and methods for the treatment of inflammatory and immune disorder...

The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising com...

The invention provides a stable solution formulation comprising a therapeutically effective amount of a GLP-1-Fc fusion protein at about pH 6.5 in citrate buffer with polysorbate-80 and mannitol. The formulation is useful in treating diabetes and obesity as well as a variety of other conditions or disorders. ...

The present invention provides formulation parameters and manufacturing conditions for stable pharmaceutical compositions comprising N-{4-(2,2-dimethyl-propionyl)-(5R)-5-[(2-ethylamino-ethanesulfonylamino)-methyl]-5-phenyl-4,5-dihydro-[1,3,4]thiadiazol-2-yl}-2,2-dimeth yl-propionamide that minimize undesirable chira...

The present invention provides crystalline 2-(6-methyl-pyridin-2-yl)-3-[6-amido- qumolin-4-yl)-5,6-dihydro-4H-pyrrolo[ l,2-b]pyrazole monohydrate.

A pharmaceutical delivery apparatus including a housing, a syringe assembly, and a needle cap. The syringe assembly is plungeable relative to the housing from a first position, at which its needle tip is disposed within the housing, to a second position, at which its needle tip projects from the housing beyond the p...

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where R6 is -C=C-R10, -CH=CR11R11" , or -(C0-C8)alkyl-Ar...

Compound and pharmaceutical compositions of Forumla by blockade of the CB1 receptors via an inverse agonism mechanism, and are useful for reducing body weight in mammals, cognitive impairment associated with schizophrenia, mitigating treatment emergent weight gain observed during treatment with antipsychotics and ha...

The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.

Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or...

The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compo...

The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising com...

An article of manufacture comprising packaging prasugrel tablets, caplets, capsule or other solid form of prasugrel in an air and/or moisture impervious container under a positive liquid gas pressure.

The present invention provides compounds of Formula I: useful in the treatment of cancer and inflammatory diseases.

The present invention relates to novel compounds, (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-yl-vinyl)pyridin-3-yl]methanone benzoate, and (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-yl-vinyl)pyridin-3-yl]methanone toluate, which are useful intermediates for the preparation of the compound of Formula I: (I) The prese...

The present invention relates to a melanin concentrating hormone antagonist compound of formula (I): wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases. ...

Anti-IL-17 antibodies are identified that are characterized as having a high affinity and slow off rate for human IL-17. The antibodies of the invention may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen- binding fragments thereof. The antibodies of the invention a...

The present invention relates to a melanin concentrating hormone antagonist compound of formula I: wherein " " is absent or is optionally a bond; q is 1 or 2; R1 is independently selected from hydrogen, -C1-C2 alkyl, halo, hydroxy, -C1-C2 haloalkyi, -C1-C3 alkoxy, cyano, -O-C3-C4 cycloalkyl, and -OC1-C2 haloalkyi;...

The present invention provides novel imidazolidinonyl aminopyrimidine compounds believed to have clinical use for treatment of cancer through inhibiting Plk1. Formula I wherein: R1 is aminomethyl, (C1-C3 alkyl)aminomethyl, di(C1-C2 alkyl)aminomethyl, N- ethyl-N-methyl-aminomethyl, 1-aminoethyl, 1-((C1-C2 alkyl)amino...

The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention disclose pharmaceutical...

The invention provides a pharmaceutically elegant solid oral formulation of olanzapine and a process for making such formulation.

wherein me variables X) to X1, R1 to R7 including R3, E, q, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed. ...

This present invention provides a composition that is suitable for administration to a human subject comprising an anti-Abeta antibody that is free of Abeta peptide or that has acceptably low levels thereof, free of non-human Abeta peptide or that has acceptably low levels thereof, or having an undetectable concentr...

A medication dispensing apparatus with a spring-driven locking feature. The apparatus includes a drive member movable in a distal direction within a housing, and a fluid container with a movable piston that is advanceable by the drive member when such drive member is moved distally by a driving means. The apparatus ...

The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or unsubstituted group selected from C1-C8 alkyl, aryl-C0-2-alkyl, heteroaryl-C0-2-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl or phenyl...

The invention provides a stable solution formulation comprising a GLP-1-Fc fusion at a pH between about pH 6 and about pH 8.5 analogs fused to specific IgG4-Fc derivatives. These formulations provide unexpected and considerably greater chemical stability than when compared to GLP-1-Fc fusions at a pH outside the des...

A pen delivery device and a procedure for administering parathyroid hormone is provided to allow for the priming and injection of a single predetermined dose. The method is a three-step method using visual indicators to set the priming and injectable dose deliveries. The device is made of a minimal number of part...

The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or unsubstituted group selected from C1-C8 alkyl, aryl-CO-2-alkyl, heteroaryl-CO-2-alkyl, C3-C6 cycloalkylaryl-CO-2-alkyl or phenyl...

The present invention relates to novel amide prodrugs of gemcitabine, compositions thereof and methods for using.

The present invention provides Compound (I): or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with one or more pharmaceutically acceptable carriers, excipients, or diluents; and methods for the treatment of inflammatory and immune disorders compris...

The present invention is concerned with certain novel spiro substituted heterocyclic ring derivatives. These compounds may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenase. They may also be useful in the manufacture of pharmaceutical formulations for the ...

A selective kappa opioid receptor antagonist having the Formula (I) useful for treating ethanol use disorder withdrawal and anxiety, and/or depression, or schizophrenia as independent comorbid conditions.

The present invention relates to a melanin concentrating hormone antagonist compound of formula (I); wherein w, R1, q, p, R2, t, Ar1, L1, R3 and R4 are as defined, or a pharmaceutically acceptable salt, solvate, or enantiomer thereof useful in the treatment, prevention or amelioration of symptoms associated with ...

The present invention is concerned with certain novel derivatives of Formula (I): wherein X and R1 to R10 are as described in the specification, and where either R5 is OH, -NRdORa or NRd-NRbRc, or R7 is -NRdORa or NRd-NRbRc, or C=R7R8 is C=NORa or C=N-NRbRc, which may be useful in the manufacture of pharmaceutical...

The present invention relates to crystalline non-solvated 1-(4-2-piperidinylethoxy)phenoxy)-2-(4-methanesulfonylphenyl)-6-hydroxynaphthalene hydrochloride, useful as a selective estrogen receptor modulator.

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have glucagon receptors antagonist or inverse agonist activity, as well as methods of using these compounds and intermediates and methods for preparing such compounds. In another embodiment, the inven...

The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (1) and methods of using these compounds.

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical comp...

This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical composition comprising, the compounds for treatment of neurological disorders and psychiatric disorders.

ABSTRACT; "SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS" The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical comp...

The present invention is concerned with certain derivatives of Formula:(I). wherein R. R1 to R10 are as described in the specification, and at least one of CR5R6, or CR7R8, or CR9R10 is a an optionally substituted azetidine ring or an optionally substituted oxetan ring, which may be useful in the manufacture of p...

The present invention relates to a stabilized composition for reducing the risk of bone fracture and increasing toughness or stiffness of bone at a site of potential for actual trauma. Further, the invention also relates to methods for increasing the toughness and/or stiffness of bond and/or reducing the likeliho...

An insoluble composition, comprising: a) a protein selected from the group consisting of insulin, insulin analog, and proinsulin; b) a derivatized protein selected from the group consisting of derivatized insulin, derivatized insulin analog, and derivatized proinsulin; c) a complexing compound; d) a hexamer-s...

The present invention relates to glucagon receptor polypeptide antagonists which inhibit the binding of the hormone glucagon to its receptor. More particularly, the present invention relates to high affinity glucagon receptor antibodies or Fab fragments thereof that inhibit binding of glucagon to its receptor and th...

CB-1 receptor inverse agonist compounds of Formula and pharmaceutical compositions for the treatment of obesity or cognitive impairment associated with schizophrenia.

The present invention, provides isolated proteins comprising beta-lipotropin (3LT), analogs thereof, fragments thereof, nucleic acids encoding same, and methods for producing and using BLT in the treatment of diabetes and complications associated therewith.

CB-1 receptor inverse agonist compounds of Formula and pharmaceutical compositions for the treatment of obesity or cognitive impairment associated with schizophrenia.

This invention relates to a series of tetracyclic derivatives, to processes for their preparation, pharmaceutical compositions containing them, and their use as therapeutic agents. In particular, the invention relates to tetracyclic derivatives which are potent and selective inhibitors of cyclic guanosine 3",5"-mono...

The present invention discloses novel compounds of Formula I: having 11β -HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compos...

TITLE: A 1 H-SUBSTITUTED-INDOLE-3-GLYOXYLAMIDE COMPOUND AND PROCESS OF PREPARATION THEREOF. A class of novel 1H-substituted-indole-3-glyoxylamides is disclosed together with the use of such indile compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock. ...

The present invention discloses novel compounds of Formula I: ( I ) possessing 11β -HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds ...

The present invention provides a method for inhibiting bone loss comprising administering to a human in need thereof a first compound selected from 1) triarylethylenes; 2) 2,3-diaryl- 2H-1-benzopyrans, 3) l-aminoalkyl-2-phenylindoles; 4) 2-phenyl- 3-aroylbenzothiophenes, 5) l-substituted-2-aryl- dihydronaphthal...

The present invention is directed to a novel,non-solvated,crystalline from of 6-hydroxy-2-(4-hydroxypheny1)-3-[4-(2-piperidinoethoxy)benzoy1]benzo[b]thiophene hydrochloride.

A Form III of (R)-7-acetyl-5-(4-aminophenyl)-8, 9-dihydro-8-methyl-7H-1, 3-dioxolo[4,5-h][2,3]benzodiazepine having an X-ray powder diffraction pattern with d spacings at 10.61, 8.83, 6.78, 5.83, 4.13 and 3.74 A. The compound is useful as an AMPA antagonist.

The present invention provides a compound of formula I wherein R1 is -H, -OH, -O(C1-C4 alkyl), -OCOC6H5, -OCO(C1-C6 alkyl), or -OSO2(C4-C6 alkyl); R2 is -H, -OH, -0(C1-C4 alkyl), -OCOC6H5, -OCO(C1-C6 alkyl) or -OSO2(C4-C6 alkyl); n is 2 or 3; and R3 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimet...

A crystalline form of (R)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-l,3-dioxolo[4,5-h][ 2,3]benzodiazepine having an X-ray powder diffraction pattern with d spacings at 12.78, 9.48, 8.99, 8.64, 8.23, 6.39, 6.27. 5.73, 4.01 and 3.96 A'. The compound is useful as an AMPA antagonist.

The present invention provides a method for treating anxiety in humans using heterocyclic compounds.

The present invention discloses novel compounds of Formula: possessing I 1β-1 ISO type I antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and co...

The present invention relates to the field of diabetes. More particularly, the invention relates to a monomeric insulin analog wherein the A chain is the naturally occurring sequence of the human insulin A chain and the B chain is modified at either position B28 and B29 or both. The analog is mono-acylated at the N-...

This invention provides a process for preparing gemcitabine hydrochloride which comprises deblocking β-1- (2"-deoxy-2",2"-difluoro-3",5"-di-O-benzoyl-D- ribofuranosyl)-4-aminopyrimidin-2-one with a catalytic amount of an alkylamine in the presence of methanol or ethanol in an environment essentially free of wat...

The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating ...

N/A

The present invention relates to AMPA receptor potentiators of Formula (I), formulations comprising them, methods for their use, and intermediates useful for their preparation.

A solid oral pharmaceutical formulation comprising 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno (2, 3-b)(1,5) benzodiazepine(olanzapine) as an active ingredient alongwith a bulking agent; binder, disintegrant, a dry binder to assure adequate; friability, and a lubricant; wherein such solid oral composituion is ...

The invention provides novel benzothiophenes of the formula (I): wherein R1 is N-pyrrolidinyl or N-piperidinyl; R2 and R3 are independently hydrogen,-CO-(C10-C22 alkyl), -CO-(C10-C22 branched alkyl), -CO-(C10-C22 alkenyl), -CO-(C10-C22 polyalkenyl), -CO-(C10-C22 alkynyl),or -CO-(CH2)nCOR4; provided R2 and R...

This invention provides compounds of the formula: The invention further provides the use of this compound to prepare N,N'-bridged bisindolylmaleimides. Furthermore, the invention provides pharmaceutical formulations and the methods of use for inhibiting Protein Kinase C in mammals.

The present invention relates to a melanin concentrating hormone antagonist compound of formula (I): wherein R1, Ra, Rb, R2, L1, R3, R4 and R5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mix...

The present invention discloses novel compounds of Formula I: ( I ) possessing 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds a...

The present invention relates to a pharmaceutical composition compnsmg a first component which is olanzapine, or pharmaceutically acceptable salt thereof in the range of 0.25 to 50 mg, once/day, and a second component which is fluoxetine, or pharmaceutically acceptable salt thereof in the range of 1 to 80 mg, once/d...

TO BE FILLED.

The present invention provides a compound of the formula : Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula (1) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disord...

A medicament comprising as an active ingredient the hydrochloride salt of a compound of the formula I said medicament pharmaceutical formulation adapted for preventing breast cancer in a postmenopausal woman human by administration for a sufficient term about 60 mg of said salt is administered. ...

The present invention provides compounds of formula (I), which are antagonists of the 5-HT6 receptor.

This invention is concerned with improved processes for reductive alkylation of glycopeptide antibiotics, the improvement residing in employing pyridine.borane as 5 reducing agent.

This invention is concerned with improved processes for reductive alkylation of glycopeptide antibiotics. The improvement residing in providing a source of copper which 5 results in the initial production of a copper complex of the glycopeptide antibiotic. Reductive alkylation of this complex favors regioselectiv...

Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases

TO BE FILLED.

A compound of the formula (I) wherein ; A is phenyl or pyridyl wherein the nitrogen is at the 5-, 6-, 7- or 8-position; one of B or D is nitrogen and the other is carbon; Z is cyclohexenyl, phenyl, pyridyl, wherein the nitrogen is at the 1-, 2-, or 3-position, or a 6-membered heterocyclic ring having one het...

The present invention relates to novel crystal forms of an amide prodrug of gemcitabine, compositions thereof and methods for using.

The present invention provides amidophenoxyindazole compounds useful in the treatment of cancer.

A method and apparatus for administering a pharmaceutical. The method employs a delivery device including a housing, a pharmaceutical containing needled syringe movable within the housing, an activation button disposed at one of the housing, and wherein the housing is flared radially outward at the other end and ...

The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced capacity for O-glycosylation when expressed in yeast compared to wild- type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells fo...

Compounds of formula (I), pharmaceutical compositions comprising them, and methods for their use are described.

The present invention relates to selective allosteric potentiators of the Formula (I): or pharmaceutically acceptable salts thereof, for the treatment of disorders associated with M4 muscarinic receptors.

The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine: I where A is –C(H)= or –N=; m is 0, 1 or 2; R1 is optionally substituted phenyl, optionally substituted pyrazol-4-yl; optionally substituted imidazolyl, optionally substituted pyrid...

The present invention provides compounds of formula I: pharmaceutical compositions thereof, and methods of using the same, processes or preparing the same, and intermediates thereof.

The present invention relates to novel, non-secosteroidal, phenyl-naphthalene compounds of Formula (I): wherein R, Rl, RP, ZP, LP1, LP2 LNP, RP3, RN, and ZNP are defined herein, their preparation, pharmaceutical compositions, and methods of use.

The invention relates to the field of pharmaceutical and organic chemistry and provides an improved process for preparing the novel heptahydrate crystalline salt of multitargeted antifolate N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid.

The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described. ...

The present invention relates to novel substituted imidazo[l,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases. ...

The present invention discloses novel compounds of Formula I: having 11 Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and com...

The present invention discloses novel compounds of Formula I: (I) having 11 -HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and com...

The present invention discloses novel compounds of Formula I: ( I ) having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and c...

Antibodies specific for mature TGF Beta 1 over mature TGF Beta 2 and mature TGF Beta 3 are provided. The antibodies are characterized by CDR3 of the heavy- chain GYRX1X2X3Y wherein X1 is W or A, X2 is F or L, X3 is A, E or Y.

discloses novel compounds of Formula 1: 5 having 11β-HSD type I antagonist activity, as well as methods for preparing such compounds, in another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula 1. as well as methods of using the compounds and compositions to ...

Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.

A formulation of a compound of formula (I), prasugrel, packaged in an air and moisture impervious gas-inerted blister pack.

4-[5-(2-Amino-ethanesulfonyl)-isoquinolin-7-yl]-phenol or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt thereof as Akt inhibitors that are antineoplastic and/or antiviral agents as well as compositions comprising these compounds and methods of using these compounds. ...

The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis.

Monoclonal antibodies are provided that bind to the N-terminus of human hepcidin-25 and are characterized as having high affinity and selectivity for the polypeptide. The antibodies of the invention are useful for increasing serum iron levels, reticulocyte count, red blood cell count, hemoglobin, and/or hematocrit i...

The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.

The present invention provides AKT and p70 S6 kinase inhibitors of Formula (I). The present invention also provides pharmaceutical compositions comprising compounds of Formula (I), uses of compounds of Formula (I) and methods of using compounds of Formula (I).

Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.

A compound of the formula: ; and pharmaceutical compositions for the treatment of pain.

ABSTRACT The present invention discloses novel compounds of Formula I: ( I ) having 11-Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the co...

The present invention provides p70 S6 kinase inhibitors of the formula: pharmaceutical formulations comprising them, and methods for their use.

The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.

Provided are lactam-cyclized peptide CXCR4 antagonists useful in the treatment of cancers, rheumatoid arthritis, pulmonary fibrosis, and HIV infection.

The present invention provides novel 1 4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.

Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia.

Abstract GPR119 agonist compounds of the formula: (I) and pharmaceutical compositions for the treatment of diabetes and obesity.

The present invention relates to compounds of formula I: or a pharmaceutically acceptable acid addition salt thereof, where; X is C(R3c= or -N=; R1 is C2-C6 alkyl, substituted C2-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 ...

A compound of the formula: or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition  and a method for treating diabetes.

An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also d...

A compound of the formula: or a pharmaceutically acceptable salt thereof as well as a pharmaceutical composition, and a method for treating diabetes.

A compound of the formula (I) and pharmaceutical compositions for the treatment or prevention of pain.A compound of the formula (I) and pharmaceutical compositions for the treatment or prevention of pain.

The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

A mGlu2/3 receptor antagonist of the formula: (formula) its uses and methods for its preparation are described.

A cartridge with injection needles for an injection device. The cartridge includes a plurality of injection needle assemblies each including a hub and a needle having ends that face in a first direction. The cartridge also includes a needle assembly support defining a plurality of needle assembly accommodating cavit...

The invention provides GLP-1 compounds coupled to al leasl one polyethylene glycol molecule.or derivative thereof, resulting in a biologically active peplide with an extended haif-life and a slower clearance when compared to that of unPEGylaied peplidc. These PEGyJated OLP-1 compounds and compositions are useful in ...

Disclosed are immunogenic compositions comprising a modified live bovine viral diarrhea virus type lb (BVDV lb) and methods for their use in the formulation and administration of therapeutic and prophylactic pharmaceutical agents. In particular the invention provides immunogenic compositions and methods for preventi...

Provided are analgesic compounds and salts thereof of formula: ( I ) wherein A is: ( A ) Additionally pharmaceutical formulations and methods of use employing the above compounds are provided.

This invention relates to novel heterocycles which are antagonists at the melanin-concentrating hormone receptor 1 (MCHR1), also referred to as 11CBy, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in medicines. Compounds of the invention have the formula: (I) ...

The present invention relates to compounds that inhibit activity of the histone lysine methyltransferase Enhancer of Zeste Homolog 2 (EZH2) pharmaceutical compositions comprising the compounds and methods of using the compounds to treat cancer such as hematologic and solid tumors.

GF

A guide and follower cooperate to promote a user moving the driver relative to the housing along a travel path that operates the apparatus. The cooperating elements of the nut and the driver are disengaged when the driver is disposed in a reset segment of the travel path, and the cooperating elements of the nut and ...

Bispecific antibodies are provided that bind Calcitonin Gene Related Peptide (CGRP) and Interleukin 23 (IL 23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CGRP and IL 23. The bispecific antibodies of the invention are useful for treating various autoimmune di...

The disclosure herein includes 5 (5 (2 (3 aminopropoxy) 6 methoxyphenyl) 1H pyrazol 3 ylamino)pyrazine 2 carbonitrile (S) lactate monohydrate that inhibits Chk1/2 and is useful in the treatment of cancer.

The present invention is directed to compounds represented by the following structural formula, Formula I: wherein: (a) X is selected from the group consisting of a single bond, O, and S; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of O, C, and S; (d) W is N; (e) E is C(R3XR4)A...

The present invention relates to antibodies that bind to human CGRP compositions and kits comprising such CGRP antibodies and methods of using such CGRP antibodies for detection of human CGRP.

The present invention is directed to a novel compound, its composition and use of a compound having a structural formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomers thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor ...

"BICYCLIC SUBSTITUTED INDOLE-DERIVATIVE STEROID HORMONE NUCLEAR RECEPTOR MODULATORS" The present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrie...

The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.

The present invention relates to an extended release once daily pharmaceutical formulation comprising venlafaxine hydrochloride and pharmaceutically acceptable excipients. More particularly, the present invention relates to an extended release composition in the form of mini-tablets which are incorporated in hard ge...

The present invention discloses compounds of formula I wherein A, n, q, K, W, X, Y, Z, R1, R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and its sequelae.

Compounds of Formula I wherin n,q,Y,R1,R2a,R2b,R3a,R3b,R4,R5,and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.

Compounds of Formula (I): wherein n, m, p, q, Y, R1 R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.

The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising com...

The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compo...

1-(lndole-6-carbonyl-D-phenylglycinyl)-4-(1-methyl-piperidin-4-yl) piperazine D-tartrate forms a stable crystalline salt and is an inhibitor of the serine protease, Factor Xa, useful in the treatment of cardiovascular disorders.

Antibodies are provided that specifically bind seven human ELR CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases such as inflammatory bowel disease (IBD) plaque psoriasis and palmoplantar pustulosis; and cancer such as renal cancer or ovarian cancer. ...

The present invention relates to antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9) or antigen binding fragments thereof compositions comprising such PCSK9 antibodies or antigen binding fragments and methods of using the same for the treatment of hyperlipidemia or hypercholesterolemia. ...

The present invention provides a method for preventing and/or treating a patient with acute kidney injury caused by a variety of conditions. The method comprises administering to the patient soluble thrombomodulin variants that do not bind thrombin. In conjunction with standard of care, soluble thrombomodulin varian...

Bispecific antibodies are provided that specifically bind B cell Activating Factor of the TNF Family (BAFF) and Interleukin 17A (IL 17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL 17. The bispecific antibodies of the invention are expected to be useful in trea...

The present invention provides selective 5-HT7 receptor antagonist compounds of Formula I and their use in the treatment of migraine, persistent pain, and anxiety: where A and B are each independently C(H)= or N=, provided that at least one of A and B is -N=, n is 1-3, m is 0-3, and R14 are as defined herein. ...

A stabilized composition for reducing the risk of bone fracture and increasing toughness or stiffness of bone at a site of potential for actual trauma, said composition comprising : a) a therapeutically effective amount of a parathyroid hormone selected from the group of PTH (1-31).PTH (1-34).PTH (1-37),PTH (1-38) a...

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.

A cartridge (260) with injection needles for an injection device. The cartridge includes a plurality of injection needle assemblies (385), each including a hub and a needle. Each needle has ends that both face in a first direction. Each hub has one portion movable relative to another hub portion between a ready arra...

A dispenser (10, 10.1) for medication is disclosed which dispenser comprises a marker (18, 24) and a set of indicia, the indicia being recognisable by the user of the dispenser as indicating meals that are taken during each day. The marker and indicia are displaceable with respect to one another so that the juxta...

A trigger assembly for an automatic injection device which by its operation releases a biased element of the device for movement. The trigger assembly includes a button pressable by a user and a lock member. Prior to the button being plunged a blocking element on the button is abutted by a button engaging surface of...

Methods for reducing the environmental impact of animal waste are described. In particular embodiments the methods comprise administering to an animal an enzyme such as alkaline phosphatase that is effective to reduce the amount of a detrimental compound such as ammonia or phosphorous that is present in or released ...

The present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly...

The present invention discloses novel compounds of Formula (I): having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods of using the compounds and com...

This present invention relates to pharmacologically potent and/or stable variants of human fibroblast growth factor 21 (FGF21) pharmaceutical compositions comprising FGF21 variants and methods for treating type 2 diabetes obesity dyslipidemia or metabolic syndrome or any combination thereof using such variants. ...

The present invention provides for novel compounds of formula I wherein X is S or S(O); R1 and R2 are each independently selected from the group consisting of -CH2CH3 and phenyl; or R1 and R2 combine to form morpholino; and processes to prepare arzoxifene.

The present invention provides an amino pyrazole compound which is 3 [(lR) 6 fluoro 2 3 dihydro 1H inden l yl] N (3 methyl IH pyrazol 5 yl) 3H imidazo[4 5 b]pyridin 5 amine or a pharmaceutically acceptable salt thereof that inhibits JAK1 and JAK2 and therefore may be useful in treating cancer.

A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope fall within the scope of the invention and may be murine, chimeric, or humanized antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies o...

The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof. Also the present invention provides a pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The present invention...

Provided are novel methods and formulations for topically controlling ectoparasite infestations in animals using spinetoram or a pharmaceutically acceptable salt thereof.

The present invention provides compounds of Formula I. Wherein Rl L and A are as described herein or a pharmaceutical salt thereof processes for preparing the compounds and methods of treating a condition such as hypertriglyceridemia using the compounds.

The present invention provides compounds of formula I: pharmaceutical compositions thereof, and methods of using the same, processes or preparing the same, and intermediates thereof.

This invention provides compositions and methods useful for treating cancers, in particular, cancers that are not multi drug resistant. The methods of the present invention include the 2",2"-difluoronucleoside anti-cancer agents described in US Patent 5,464,826 in combination with leukotriene (LTB4) antagonists...

A method and medicament for treating mixed lineage leukemia; translocated mixed lineage leukemia; translocated mixed lineage leukemia based acute myelogenous leukemia; translocated mixed lineage leukemia based acute lymphoid leukemia; a non-MLL based chronic myeloproliferative disorder, or non-MLL based acute lympho...

A method to treat conditions associated with Aß peptide activity both prophylactically and therapeutically is described. The method employs humanized antibody fragments that specifically bind human Aß peptide between amino acid positions 13-28, wherein the antibody fragments are covalently attached to a polyethy...

Compounds of Formula (I), wherein n is 1 or 2, and R1, R2, R3, R4, R5, R6, R7, and R8 are as defined herein, their preparation, pharmaceutical compositions, and methods of use are disclosed.

This invention provides a process to prepare 10,11-(optionally substituted)methanodibenzosuberne derivatives. The invention also provides an intermediate in this process.

The present invention provides triazolyl aminopyrimidine compounds useful in the treatment of cancer.

The present invention relates to anti-human CD226 agonist antibodies, which can be useful for treating solid tumor cancers.

Novel selective estrogen receptor degraders (SERDs) according to the formula: pharmaceutically acceptable salts, pharmaceutical compositions, uses, and methods of use thereof are provided.

Novel selective estrogen receptor degraders (SERDs) according to the formula:, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein either R1 or R2 is independently selected from Cl, F, -CF3, or -CH3, and the other is hydrogen, and methods for their use are provided. ...

Disclosed herein are systems and methods for remote prescription of medication-dosing regimens. One embodiment takes the form of a method that includes presenting, via a healthcare- professional-(HCP)-portal user interface of an HCP system, multiple medication-dosing regimens pertaining to a patient. Each presented ...

The present invention provides the following compounds or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing said compounds useful as a Notch pathway signaling inhibitor for the treatment of named cancers sensorineural hearing loss caused by auditory hair cell loss and inducing audi...

An injection device assembly including a housing, a syringe, a drive mechanism and one or more sensing systems are described. The drive mechanism advances the syringe from a storage position to an injection position, and a plunger advances the syringe piston from an initial position to a final position. The status s...

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof for use as a human PDE1 inhibitor.

The present invention provides a compound or a pharmaceutically acceptable salt of the Formula : X1 I V X2 S L D V P I G L L Q I L X3 E Q E K Q E K E K Q Q A K* T N A X4 I L A Q V-NH2 wherein the X1 denotes that the I residue is modified by either acetylation or methylation at the N-terminus; wherein X2 is L or T; w...

The invention provides compounds of the formula: (A) pharmaceutically acceptable salts pharmaceutical compositions thereof and methods of using these compounds salts or compositions to treat hyperphosphatemia chronic kidney disease and/or the cardiovascular diease associated with chronic kidney disease. ...

Methods for determining protein and/or peptide concentration or molecular parameter, such as the extinction coefficient, and uses thereof.

The present invention provides compounds of the Formula (I), or a pharmaceutically acceptable salt thereof, where n and R1 are defined herein, methods of treating patients for liver disease, and processes for preparing the compounds.

The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

The present invention provides a compound of formula (I) or a pharmaceutical salt thereof, use, methods for its preparation are described.

Abstract Compounds of a formula entitled, trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol- 5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]- cyclohexanecarboxylic acid, as a free acid or a pharmaceutically acceptable salt thereof, hydrate, and hydrate in cryst...

The present invention provides 5-[5]-[2-cycloa Ikyl ]-6-pyridazin-3-yl ]- IH-pyrimidine-2,4-dione compounds, or pharmaceutically acceptable salts thereof, that inhibit the activity of CD73 and are useful in treating cancer. (Formula (I))

The present invention provides phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds, to pharmaceutical compositions comprising the compounds, to methods of using the compounds to treat physiological disorders such as cancer.

The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula (I) for treatment of neurodegenerative diseases and disorders, such as Alzheimer"s disease.

The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration useful in the treatment of hypoglycemia and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation and to devices and metho...

The present invention relates to novel aminopyridyloxypyrazole compounds that inhibit the activity of transforming growth factor beta receptor 1 (TGFpRI) pharmaceutical compositions comprising the compounds and methods of using the compounds to treat cancer preferably colon cancer melanoma hepatocellular carcinoma r...

The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.